CN112655816A - Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof - Google Patents
Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof Download PDFInfo
- Publication number
- CN112655816A CN112655816A CN202011563424.0A CN202011563424A CN112655816A CN 112655816 A CN112655816 A CN 112655816A CN 202011563424 A CN202011563424 A CN 202011563424A CN 112655816 A CN112655816 A CN 112655816A
- Authority
- CN
- China
- Prior art keywords
- parts
- feed additive
- feed
- dried powder
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003445 Ascites Diseases 0.000 title claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 41
- 239000003674 animal food additive Substances 0.000 title claims abstract description 40
- 241000283690 Bos taurus Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 30
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 24
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 24
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 24
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 24
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 24
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 23
- 239000003613 bile acid Substances 0.000 claims abstract description 23
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 18
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000010081 allicin Nutrition 0.000 claims abstract description 18
- 229920002261 Corn starch Polymers 0.000 claims abstract description 16
- 239000008120 corn starch Substances 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 230000004584 weight gain Effects 0.000 claims abstract description 8
- 235000019786 weight gain Nutrition 0.000 claims abstract description 8
- 241000270934 Rana catesbeiana Species 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 16
- 239000000654 additive Substances 0.000 claims description 14
- 230000000996 additive effect Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- DKPMWHFRUGMUKF-UHFFFAOYSA-N (3alpha,5alpha,6alpha,7alpha)-3,6,7-Trihydroxycholan-24-oic acid Natural products OC1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DKPMWHFRUGMUKF-UHFFFAOYSA-N 0.000 claims description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 2
- JOYGXTIHTHBSOA-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(Cl)=CC=C1C(=O)C=CC1=CC=CS1 JOYGXTIHTHBSOA-UHFFFAOYSA-N 0.000 claims description 2
- DGABKXLVXPYZII-UHFFFAOYSA-N Hyodeoxycholic acid Natural products C1C(O)C2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 DGABKXLVXPYZII-UHFFFAOYSA-N 0.000 claims description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 2
- DGABKXLVXPYZII-SIBKNCMHSA-N hyodeoxycholic acid Chemical compound C([C@H]1[C@@H](O)C2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 DGABKXLVXPYZII-SIBKNCMHSA-N 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 10
- 210000004185 liver Anatomy 0.000 abstract description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 8
- 241000555712 Forsythia Species 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000000857 drug effect Effects 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 3
- 230000036285 pathological change Effects 0.000 abstract description 3
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 230000034994 death Effects 0.000 description 14
- 238000009395 breeding Methods 0.000 description 12
- 230000001488 breeding effect Effects 0.000 description 12
- 241000607528 Aeromonas hydrophila Species 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 241000269350 Anura Species 0.000 description 6
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000000384 rearing effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000021316 daily nutritional intake Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AZJQQNWSSLCLJN-UHFFFAOYSA-N 2-ethoxyquinoline Chemical compound C1=CC=CC2=NC(OCC)=CC=C21 AZJQQNWSSLCLJN-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910003424 Na2SeO3 Inorganic materials 0.000 description 1
- 241000410394 Odorrana grahami Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000270936 Pelophylax esculentus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241000269436 Ranidae Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052927 chalcanthite Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
- Y02A40/818—Alternative feeds for fish, e.g. in aquacultures
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
The invention relates to a feed additive for preventing and treating bovine frog ascites disease, a preparation method and application thereof, wherein the feed additive comprises the following components in parts by weight: 15-30 parts of fructus forsythiae, 15-30 parts of radix bupleuri, 1-2 parts of allicin, 2-4 parts of bile acid, 15-25 parts of lactobacillus acidophilus freeze-dried powder, 15-25 parts of bacillus subtilis freeze-dried powder and 10-20 parts of corn starch. According to the invention, the allicin is compatible with the forsythia and the radix bupleuri to enhance the drug effect, and the combination of the bile acid, the forsythia and the radix bupleuri can effectively improve the liver function and reduce the probability of liver pathological changes; on the other hand, the lactobacillus acidophilus and the bacillus subtilis are adopted, so that the regulation and inhibition of flora in digestive tracts such as intestinal tracts and the like are facilitated, pathogenic bacteria in a water body are inhibited, the absorption of animals on nutrient substances is promoted, and the feed conversion rate is improved; finally, the combination of traditional Chinese medicines and beneficial bacteria has no side effect, can prevent and treat ascites disease, reduce feed coefficient and improve weight gain rate, and the combination of the traditional Chinese medicines and the beneficial bacteria obviously enhances the effects and improves economic benefit.
Description
Technical Field
The invention relates to a feed additive, in particular to a feed additive for preventing and treating bovine frog ascites disease and a preparation method and application thereof.
Background
Bullfrog (Rana catesbeian) belongs to Amphinaceae, Anhula, Ranidae, and is a large edible frog because it sounds like a cow. The bullfrog is originally produced in North America, Mexico and other places, is introduced into China from Gouba in 1959, is a meat food with high protein, low fat and low cholesterol, has delicious taste, high growth speed and strong environmental adaptability, and has wide consumption market at home and abroad. In 2019, the breeding yield of bullfrogs in China is close to 50 million tons, the direct sale yield exceeds 50 million yuan per year, and the bullfrogs become important famous and special varieties for aquaculture in China.
In the process of breeding bullfrogs, ascites diseases are easy to occur in high-temperature seasons, and are very common particularly under the conditions of water quality deterioration, high stocking density and poor management. The main symptoms of the bovine frog ascites disease are: the abdomen is enlarged, a large amount of ascites and liver enlargement are dissected; in severe cases, the diseased frog has weakness in limbs, anorexia, large amount of yellowish or reddish ascites, and congestion and inflammation of the intestinal and gastric walls. The pathogeny of the bullfrog ascites disease is mainly aeromonas hydrophila, has strong infectivity, is easy to erupt in the whole pool, causes the death of bullfrogs in a large amount in a short time, and causes serious economic loss.
Generally, farmers use sulfonamides or sars drugs for prevention and treatment, however, the existing drugs have no special effect on ascites disease, and meanwhile, due to the problems of drug resistance, drug residue influencing meat quality, high drug cost, inconvenient operation and the like, the industry needs a green feed additive capable of replacing antibiotics to solve the problems.
Disclosure of Invention
Aiming at the defects, the invention provides the feed additive, which is used for preventing and treating bullfrog ascites disease in the breeding process, reducing morbidity and mortality and improving the breeding benefit.
The invention achieves the above purposes through the following scheme:
in a first aspect, the invention provides a feed additive for preventing and treating bovine frog ascites disease, which comprises the following components in parts by weight: 15-30 parts of fructus forsythiae, 15-30 parts of radix bupleuri, 1-2 parts of allicin, 2-4 parts of bile acid, 15-25 parts of Lactobacillus acidophilus (Lactobacillus acidophilus) freeze-dried powder, 15-25 parts of Bacillus subtilis freeze-dried powder and 10-20 parts of corn starch.
In a preferred embodiment, the feed additive for preventing and treating the bovine frog ascites disease comprises the following components in parts by weight: 15 parts of fructus forsythiae, 30 parts of radix bupleuri, 2 parts of allicin, 2 parts of bile acid, 15 parts of lactobacillus acidophilus freeze-dried powder, 25 parts of bacillus subtilis freeze-dried powder and 11 parts of corn starch.
In a preferred embodiment, the feed additive for preventing and treating the bovine frog ascites disease comprises the following components in parts by weight: 30 parts of fructus forsythiae, 15 parts of radix bupleuri, 1 part of allicin, 4 parts of bile acid, 25 parts of lactobacillus acidophilus freeze-dried powder, 15 parts of bacillus subtilis freeze-dried powder and 10 parts of corn starch.
In a preferred embodiment, the feed additive for preventing and treating the bovine frog ascites disease comprises the following components in parts by weight: 20 parts of fructus forsythiae, 20 parts of radix bupleuri, 1 part of allicin, 2 parts of bile acid, 20 parts of lactobacillus acidophilus freeze-dried powder, 20 parts of bacillus subtilis freeze-dried powder and 17 parts of corn starch.
Preferably, the bile acid comprises 20% of hyocholic acid, 60% of hyodeoxycholic acid and 20% of chenodeoxycholic acid by weight percentage.
Preferably, the number of viable bacteria of the lactobacillus acidophilus freeze-dried powder after resuscitation is not less than 1 multiplied by 109cfu/g。
Preferably, the bacillus subtilis freeze-dried powder is compoundedThe number of viable bacteria after threatened is not less than 1 × 109cfu/g。
The forsythia and the radix bupleuri used in the invention are traditional Chinese herbal medicines, have broad-spectrum antibacterial action, can effectively prevent and control bacterial infection, do not generate drug resistance, have no residue and do not influence the meat quality of bullfrogs. Moreover, the bullfrog ascites is often complicated with liver lesion, and the forsythia and the bupleurum have obvious liver protection effects, can relieve the degeneration and necrosis of liver cells, and can promote the liver glycogen content to recover to normal;
the allicin used in the invention has wide pharmacological activity and broad antibacterial spectrum, has better inhibiting effect on gram-positive bacteria, gram-negative bacteria and fungi, and can enhance the drug effect by being reasonably compatible with Chinese herbal medicines of fructus forsythiae and radix bupleuri; meanwhile, the allicin has better food calling effect on aquatic animals and can promote the intake of the feed containing Chinese herbal medicines.
The bile acid is the main component of endogenous bile of animals, can dredge biliary tract, effectively decompose and remove bacterial endotoxin, mycotoxin and the like accumulated in liver and intestinal tract, and can repair liver and gall injury; the bile acid can be used together with liver-protecting Chinese herbal medicines fructus forsythiae and bupleuri radix to effectively improve liver function and reduce liver pathological change probability.
After entering the intestinal tract, lactobacillus acidophilus can release lactic acid and antibiotics such as acidophilic lactobacillus, acidophilic lactobacillus and lactein, and can generate antagonistic action on intestinal pathogenic bacteria; meanwhile, lactobacillus acidophilus is excreted into water through excrement to form dominant bacteria, and pathogenic bacteria in water can be competitively inhibited.
The bacillus subtilis also has the function of competitively inhibiting the colonization or proliferation of other external pathogenic microorganisms in the digestive tract; in addition, the bacillus subtilis grows and breeds in animal intestinal tracts, can generate various nutrient substances such as vitamins, amino acids, growth promotion factors and the like to promote animal growth, and meanwhile, the bacillus subtilis also has stronger activities of protease, lipase and amylase, can promote the absorption of the nutrient substances by animals, and improves the conversion efficiency of the feed.
In a second aspect, the invention provides a method for preparing the feed additive for preventing and treating bovine frog ascites disease, which comprises the following steps:
(1) pulverizing fructus forsythiae and bupleuri radix respectively, and sieving;
(2) mixing sieved fructus forsythiae and bupleuri radix with garlicin, bile acid, Lactobacillus acidophilus lyophilized powder, Bacillus subtilis lyophilized powder and corn starch, and stirring to obtain mixture;
(3) and (3) performing secondary crushing on the mixture obtained in the step (2), sieving, and uniformly stirring the sieved mixture to obtain the feed additive.
In a preferred embodiment, a method for preparing the feed additive for preventing and treating bovine frog ascites disease comprises the following steps:
(1) pulverizing fructus forsythiae and bupleuri radix respectively, and sieving with 40 mesh sieve;
(2) mixing fructus forsythiae and bupleuri radix sieved by a 40-mesh sieve with garlicin, bile acid, lactobacillus acidophilus lyophilized powder, bacillus subtilis lyophilized powder and corn starch, and stirring uniformly to obtain a mixture;
(3) and (3) performing secondary crushing on the mixture obtained in the step (2), sieving by using a 100-mesh sieve, and uniformly stirring the sieved mixture to obtain the feed additive.
In a third aspect, the invention provides a feed additive prepared by the preparation method.
In a fourth aspect, the invention provides an application of the feed additive for preventing and treating the bovine frog ascites disease, wherein the additive is added into the compound feed of the bovine frog in an amount of 0.5-2% by weight.
In a preferred embodiment, the feed additive for preventing and treating the bovine frog ascites disease is added into the compound feed of the bullfrog in an amount of 1 percent by weight.
The feed additive for preventing and treating the bullfrog ascites disease is used for preventing the bullfrog ascites disease and/or treating the bullfrog ascites disease, and/or increasing the weight gain rate of the bullfrog, and/or reducing the feed coefficient, and/or reducing the death rate including the death rate caused by the bullfrog ascites disease.
Compared with the prior art, the invention has the beneficial effects that:
the forsythia and the radix bupleuri with the liver protection function have the antibacterial function and the allicin for attracting food, the allicin is matched with the forsythia and the radix bupleuri to enhance the drug effect, and the bile acid, the forsythia and the radix bupleuri are used together to more effectively improve the liver function and reduce the probability of liver pathological change; on the other hand, the lactobacillus acidophilus and the bacillus subtilis are adopted, so that the regulation and inhibition of flora in digestive tracts such as intestinal tracts are facilitated, pathogenic bacteria in water are inhibited, animals are promoted to absorb nutrient substances, and the feed conversion rate is improved; finally, the invention adopts the combination of traditional Chinese medicines and beneficial bacteria, has no side effect, can prevent and treat the ascites disease, reduces the feed coefficient, improves the weight gain rate and the like, and the combination of the traditional Chinese medicines and the beneficial bacteria obviously enhances the effects and greatly improves the economic benefit.
Drawings
FIG. 1 is a graph comparing the average daily mortality in comparative test example 2.
FIG. 2 is a graph comparing the average daily mortality in comparative test example 3.
Detailed Description
The present invention is further illustrated by the following specific examples.
The formula of the common bullfrog compound feed used in the invention is as follows (in parts by weight): 16 parts of domestic semi-defatted fish meal, 10 parts of American chicken meal, 8 parts of domestic pork meal, 5 parts of soybean protein concentrate, 30 parts of soybean meal, 23 parts of high gluten flour, 1 part of refined fish oil, 3 parts of soybean oil, 2 parts of monocalcium phosphate, 1.5 parts of vitamin and mineral salt premix, 0.4 part of choline chloride, 0.05 part of antioxidant and 0.05 part of mildew preventive.
The content of crude protein in the common bullfrog compound feed is 42.7 percent, the content of crude fat is 8.8 percent, and the available energy value is 19.5 kJ/g.
Wherein, the antioxidant adopts ethoxyquinoline.
Wherein, the mildew preventive adopts propionic acid type mildew preventive.
Wherein the vitamin and mineral salt premix comprises per kg the following ingredients: 3.2g of vitamin A; vitamin D3, 0.5 g; vitamin E, 24 g; vitamin K3, 1 g; vitamin B1, 2.5 g; riboflavin (80%), 4.5 g; pyridoxine, 2 g; vitamin B12 (1%), 1 g; vitamin C (35%), 200 g; calcium pantothenate, 6g; nicotinic acid, 20 g; inositol, 80 g; biotin (2%), 6 g; folic acid, 2 g; choline chloride (50%), 250 g; FeSO4·H2O,8g;ZnSO4·H2O,5g;CuSO4·5H2O,1g;MnSO4·H2O,4.5g;KI,6g;CoCl2·6H2O(1%),5g;Na2SeO3(1%),2g;MgSO4·7H2O, 120 g; NaCl, 100 g; 100g of calcium propionate and 45.8g of cellulose.
Example 1
A feed additive for preventing and treating bovine frog ascites comprises the following components in parts by weight: 15 parts of fructus forsythiae, 30 parts of radix bupleuri, 2 parts of allicin, 2 parts of bile acid, 15 parts of lactobacillus acidophilus freeze-dried powder, 25 parts of bacillus subtilis freeze-dried powder and 11 parts of corn starch.
The using method comprises the following steps: 1 part of the prepared additive and 99 parts of common bullfrog compound feed are uniformly mixed, then are puffed and granulated, and are packaged for later use after being dried, cooled and screened.
Example 2
A feed additive for preventing and treating bovine frog ascites comprises the following components in parts by weight: 30 parts of fructus forsythiae, 15 parts of radix bupleuri, 1 part of allicin, 4 parts of bile acid, 25 parts of lactobacillus acidophilus freeze-dried powder, 15 parts of bacillus subtilis freeze-dried powder and 10 parts of corn starch.
The using method comprises the following steps: 1 part of the prepared additive and 99 parts of common bullfrog compound feed are uniformly mixed, then are puffed and granulated, and are packaged for later use after being dried, cooled and screened.
Example 3
A feed additive for preventing and treating bovine frog ascites comprises the following components in parts by weight: 20 parts of fructus forsythiae, 20 parts of radix bupleuri, 1 part of allicin, 2 parts of bile acid, 20 parts of lactobacillus acidophilus freeze-dried powder, 20 parts of bacillus subtilis freeze-dried powder and 17 parts of corn starch.
The using method comprises the following steps: 1 part of the prepared additive and 99 parts of common bullfrog compound feed are uniformly mixed, then are puffed and granulated, and are packaged for later use after being dried, cooled and screened.
Comparative test example 1
The breeding test is carried out on a certain breeding farm in south pond town of Shanfeng city, Lufeng city, Shanshan province, Guangdong province from 2019, 6 and 20 days to 2019, 10 and 18 days. Selecting 16 thousands of bullfrogs with healthy appearance and uniform specification, respectively transferring the bullfrogs into 16 test pools (15m multiplied by 4m multiplied by 1.0m, the water depth: 0.8m), and temporarily culturing 10000 bullfrogs in each pool for one week. During the temporary rearing period, the common bullfrog compound feed is used for feeding for 2 times (7:00, 17:00) every day, so that the feed is suitable for the rearing environment and feed. Then, the feed was randomly divided into 4 groups, and the feed was fed to comparative example 1 (normal bullfrog mixed feed), example 1, example 2 and example 3, 4 times per group, and manually fed at a timing of 7:00 and 17:00 per day, so that the bullfrogs were apparently satiated. The daily food intake, number of dead frogs in ascites disease and weight of dead frogs were recorded. The test period was 120 days, and the frog in each pond was weighed at the end of the test, and the test results are shown in table 1.
Table 1: comparative test example 1 Bullfrog mortality and growth Performance data
Example 1 | Example 2 | Example 3 | Comparative example 1 | |
Initial average amount (g) | 23.5±0.3 | 23.1±0.2 | 23.2±0.2 | 23.7±0.4 |
Final average dose (g) | 249.1±3.7a | 256.1±4.5a | 253.2±3.6a | 224.6±2.8b |
Weight gain (%) | 960.0±14.3a | 1008.7±17.7a | 991.4±14.1a | 847.7±10.6b |
Feed factor (weight of dead frog in calculation) | 0.93±0.01a | 0.90±0.02a | 0.92±0.02a | 1.02±0.01b |
Cost of frog feed (Yuan/jin frog) | 3.82±0.04ab | 3.70±0.06a | 3.78±0.08ab | 3.92±0.03b |
Total mortality (%) | 1.7±0.2a | 1.3±0.2a | 1.5±0.1a | 4.6±0.6b |
Ascites disease mortality (%) | 0.8±0.0a | 0.6±0.1a | 0.7±0.1a | 3.3±0.5b |
Note: 1. the difference is significant (P <0.05) for different lower case letters after the same row of data in the table; 2. the feed prices of examples 1 to 3 were calculated to 8200 yuan/ton and the feed price of comparative example 1 was calculated to 7700 yuan/ton.
As can be seen from Table 1, the final body weight and the weight gain rate of the samples 1 to 3 are all significantly higher than those of the sample 1, and the feed coefficient, the total death rate and the ascites disease death rate are all significantly lower than those of the sample 1; the above indexes are not significantly different from example 1 to example 3. The cost of the rana grahami feed in example 2 is significantly lower than that in comparative example 1, but example 1 and example 3 have no significant difference from comparative example 1, and no significant difference exists between example 1 and example 3.
The results of the comparative experiment show that the feed additive can obviously reduce the total death rate, the ascites death rate and the feed coefficient of the bullfrogs, and simultaneously obviously improve the growth speed of the bullfrogs, and has obvious overall economic benefit.
Comparative test example 2
The breeding contrast test is carried out on a certain farm in Chenghai district, Yanhong town of Shantou city, Guangdong province from 8 months 6 days in 2019 to 8 months 20 days in 2019. The farm has 6 culture ponds with the same specification (20m multiplied by 6m multiplied by 1m, the water depth is 0.8m, the tail of each pond is placed with a frog 18000 without loss before the pond), a small amount of bullfrogs in each pond are found to have abdominal dropsy at the bottom of 7 months, then the water change amount is increased every day and the whole pond is disinfected, the improvement is still not good by 5 days after 8 months, and the morbidity and the mortality are continuously increased. The comparative treatment protocol was started at 6.8 months and 6 ponds were randomly divided into 2 groups of 3 replicates each, the first group was fed with norfloxacin mix (comparative example 2) at 2g/kg feed and the second group was fed with the feed of example 2, and the bullfrogs were apparently satiated by manual feeding at 7:00 and 17:00 times per day. And (4) the comparison period is 15 days, the death number of each pool is recorded every day, water samples of each pool are collected at the beginning, the end and the 7 th day of the comparison, and the number of aeromonas hydrophila in the water body is detected. The test results are shown in FIG. 1 and Table 2.
Table 2: comparative test example 2 the number of Aeromonas hydrophila in Water
Note: the difference is significant for different lower case letters after the same row data in the table (P <0.05)
As can be seen from fig. 1, the average daily mortality in example 1 was significantly lower than that in comparative example 1, and death had ceased at day 8-19, whereas the mortality in comparative example 1 did not change significantly after day 8-14 and continued to be high.
As can be seen from Table 2, the number of Aeromonas hydrophila in the water body on the 7 th day of the comparison and at the end of the comparison in the comparison period of example 2 was also significantly lower than that in comparative example 2.
The results of the test show that the additive can effectively prevent and treat the bovine frog ascites disease by adding into the feed, and the effect is obviously better than that of norfloxacin.
Comparative test example 3
The breeding contrast test is carried out on a certain breeding farm in the south town of the Chenghai district xi of Shantou city of Guangdong province from 9 months 9 to 19 months 9 and 2019 in 2019. The farm has 10 culture ponds with the same specification (15m multiplied by 6m multiplied by 1m, the water depth is 0.8m, 10000 frogs are placed in each pond without loss before the pond), a small amount of frogs in each pond are found to have ascites disease in the early 9 months, then the water change amount is increased every day and the whole pond is disinfected, the disease rate and the death rate are continuously increased after 9 months and 8 days. The comparative treatment scheme was started on 9 months and 9 days, 10 breeding ponds were randomly divided into 2 groups, each group was repeated 5 times, the first group was fed with the compound sulfamethoxazole mix (comparative example 3) at a dose of 3g/kg feed, and the second group was fed with the feed of example 3 at regular times of 7:00 and 17:00 per day to apparently satiate bullfrogs. And (3) the comparison period is 11 days, the death number of each pool is recorded every day, water samples of each pool are collected at the beginning, the end and the 7 th day of the comparison, and the number of aeromonas hydrophila in the water body is detected. The test results are shown in fig. 2 and table 3.
Table 3: comparative test example 3 the number of Aeromonas hydrophila in Water
Note: the difference is significant for different lower case letters after the same row data in the table (P <0.05)
As can be seen from fig. 2, the average daily mortality in example 3 was significantly lower than that of comparative example 3, and death had ceased at 19 days 9 months, whereas the mortality in comparative example 3 did not change significantly after 15 days 9 months and continued to stay high.
As can be seen from Table 3, the number of Aeromonas hydrophila in the water body on the 7 th day of the comparison and at the end of the comparison in example 3 was also significantly lower than in comparative example 3 during the comparison period.
The results of the test show that the additive can effectively prevent and treat the bovine frog ascites disease by adding into the feed, and the effect is obviously better than that of the compound sulfamethoxazole.
Comparative test example 4
To show the synergistic effect of the components in the additive of the present invention, 6 additives lacking a single component were prepared on the basis of example 1. The 1 st lacks fructus forsythiae, the 2 nd lacks radix bupleuri, the 3 rd lacks bile acid, the 4 th lacks allicin, the 5 th lacks lactobacillus acidophilus freeze-dried powder and the 6 th lacks bacillus subtilis freeze-dried powder. The 6 single component missing additive formulations are shown in table 4.
Table 4: example 1 and deficiency formulations
The breeding test is carried out on a certain breeding farm in south pond town of Shanfeng city, Lufeng city, Shanshan province, Guangdong province from 2019, 6 and 20 days to 2019, 10 and 18 days. Selecting 28 thousands of bullfrogs with healthy appearance and uniform specification, respectively transferring the bullfrogs into 28 test ponds (15m multiplied by 4m multiplied by 1.0m, the water depth: 0.8m), and temporarily culturing 10000 bullfrogs in each pond for one week. During the temporary rearing period, the common bullfrog compound feed is used for feeding for 2 times (7:00, 17:00) every day, so that the feed is suitable for the rearing environment and feed. Then, the bullfrog is randomly divided into 7 groups, each group is repeated for 4 times, the feeds of the embodiment 1 and the deletion examples 1-6 are respectively fed, and the bullfrog is artificially fed at the fixed time of 7:00 and 17:00 every day to ensure that the bullfrog is apparently satiated. The daily food intake, number of dead frogs in ascites disease and weight of dead frogs were recorded. The test period was 120 days, and the frog in each pond was weighed at the end of the test, and the test results are shown in table 5.
Table 5: comparative experiment 4 for bullfrog mortality and growth performance data
As can be seen from table 5, the terminal body weight, the weight gain rate and the feed factor of example 1 are not significantly different from those of deletion examples 1 and 2, but the terminal body weight and the weight gain rate of example 1 are significantly higher than those of deletion examples 3 to 6, and the feed factor is significantly lower than those of deletion examples 3 to 6; the total mortality rate and ascites disease mortality rate of example 1 were significantly lower than those of deletion examples 1-6.
The results of the comparative experiments show that the feed additive can obviously reduce the total death rate, the ascites death rate and the feed coefficient of bullfrogs, and simultaneously obviously improve the growth speed of the bullfrogs, and the components of the feed additive have synergistic action.
In addition, the inventor further researches the effect of the weight ratio of the components in the feed additive disclosed by the invention by using similar experiments, and proves that the mortality rate, the ascites disease mortality rate and other effects are better by using the weight ratio disclosed by the invention, so that the effect of the feed additive is remarkably improved by using the weight ratio disclosed by the invention.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and their concepts should be considered to be equivalent or modified within the technical scope of the present invention.
Claims (10)
1. The feed additive for preventing and treating the bovine frog ascites disease is characterized by comprising the following components in parts by weight: 15-30 parts of fructus forsythiae, 15-30 parts of radix bupleuri, 1-2 parts of allicin, 2-4 parts of bile acid, 15-25 parts of lactobacillus acidophilus freeze-dried powder, 15-25 parts of bacillus subtilis freeze-dried powder and 10-20 parts of corn starch.
2. The feed additive for preventing and treating bovine frog ascites disease according to claim 1, which is characterized by comprising the following components in parts by weight: 15 parts of fructus forsythiae, 30 parts of radix bupleuri, 2 parts of allicin, 2 parts of bile acid, 15 parts of lactobacillus acidophilus freeze-dried powder, 25 parts of bacillus subtilis freeze-dried powder and 11 parts of corn starch.
3. The feed additive for preventing and treating bovine frog ascites disease according to claim 1, which is characterized by comprising the following components in parts by weight: 30 parts of fructus forsythiae, 15 parts of radix bupleuri, 1 part of allicin, 4 parts of bile acid, 25 parts of lactobacillus acidophilus freeze-dried powder, 15 parts of bacillus subtilis freeze-dried powder and 10 parts of corn starch.
4. The feed additive for preventing and treating bovine frog ascites disease according to claim 1, which is characterized by comprising the following components in parts by weight: 20 parts of fructus forsythiae, 20 parts of radix bupleuri, 1 part of allicin, 2 parts of bile acid, 20 parts of lactobacillus acidophilus freeze-dried powder, 20 parts of bacillus subtilis freeze-dried powder and 17 parts of corn starch.
5. The feed additive for preventing and treating bovine frog ascites as claimed in any one of claims 1 to 4, wherein the bile acid comprises 20% by weight of hyocholic acid, 60% by weight of hyodeoxycholic acid, and 20% by weight of chenodeoxycholic acid; and/or the viable count of the lactobacillus acidophilus freeze-dried powder after recovery is not less than 1 multiplied by 109cfu/g; and/or the number of viable bacteria after the bacillus subtilis freeze-dried powder recovers is not less than 1 multiplied by 109cfu/g。
6. A method for preparing the feed additive for preventing and treating bovine frog ascites disease of any one of claims 1 to 5, comprising the following steps:
(1) pulverizing fructus forsythiae and bupleuri radix respectively, and sieving;
(2) mixing sieved fructus forsythiae and bupleuri radix with garlicin, bile acid, Lactobacillus acidophilus lyophilized powder, Bacillus subtilis lyophilized powder and corn starch, and stirring to obtain mixture;
(3) and (3) performing secondary crushing on the mixture obtained in the step (2), sieving, and uniformly stirring the sieved mixture to obtain the feed additive.
7. The method of claim 6, comprising the steps of:
(1) pulverizing fructus forsythiae and bupleuri radix respectively, and sieving with 40 mesh sieve;
(2) mixing fructus forsythiae and bupleuri radix sieved by a 40-mesh sieve with garlicin, bile acid, lactobacillus acidophilus lyophilized powder, bacillus subtilis lyophilized powder and corn starch, and stirring uniformly to obtain a mixture;
(3) and (3) performing secondary crushing on the mixture obtained in the step (2), sieving by using a 100-mesh sieve, and uniformly stirring the sieved mixture to obtain the feed additive.
8. A feed additive prepared by the preparation method according to claim 6 or 7.
9. The application of the feed additive for preventing and treating the bullfrog ascites is characterized in that the additive is the additive disclosed in any one of claims 1-5 and 6-7, and the additive is added into a bullfrog compound feed in an amount of 0.5-2% in percentage by weight; preferably, the additive is added into the bullfrog compound feed in a weight percentage of 1%.
10. Use of a feed additive for the prevention and treatment of bullfrog ascites disease, characterised in that the additive is a feed additive according to any one of claims 1 to 5 and 6 to 7 for the prevention and/or treatment of bullfrog ascites disease and/or for increasing the rate of weight gain and/or for reducing the feed factor and/or for reducing the mortality rate, including mortality due to ascites disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011563424.0A CN112655816A (en) | 2020-12-25 | 2020-12-25 | Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011563424.0A CN112655816A (en) | 2020-12-25 | 2020-12-25 | Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112655816A true CN112655816A (en) | 2021-04-16 |
Family
ID=75409167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011563424.0A Pending CN112655816A (en) | 2020-12-25 | 2020-12-25 | Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112655816A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215057A (en) * | 2021-06-08 | 2021-08-06 | 集美大学 | Rana-sourced lactococcus lactis subspecies lactis LCLL1 and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108522860A (en) * | 2018-07-09 | 2018-09-14 | 山东龙昌动物保健品有限公司 | Application of the bile acid in preparing the feed addictive for bullfrog |
-
2020
- 2020-12-25 CN CN202011563424.0A patent/CN112655816A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108522860A (en) * | 2018-07-09 | 2018-09-14 | 山东龙昌动物保健品有限公司 | Application of the bile acid in preparing the feed addictive for bullfrog |
Non-Patent Citations (5)
Title |
---|
官少飞等: "《一本书明白鲤鱼健康养殖关键技术》", 31 August 2017, 江西科学技术出版社 * |
戈贤平: "《专家与成功养殖者共谈—现代高效大宗淡水鱼养殖实战方》", 31 December 2015, 金盾出版社 * |
李清: "《水生动物疾病与安全用药手册》", 30 April 2014, 海洋出版社 * |
林亦斌等: "大蒜素在水产养殖中的应用", 《广东饲料》 * |
王玉堂: "《有益微生物制剂及其在水产养殖中的应用》", 31 July 2018, 海洋出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215057A (en) * | 2021-06-08 | 2021-08-06 | 集美大学 | Rana-sourced lactococcus lactis subspecies lactis LCLL1 and application thereof |
CN113215057B (en) * | 2021-06-08 | 2022-12-16 | 集美大学 | Rana-sourced lactococcus lactis subspecies lactis LCLL1 and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jazi et al. | Fermented soybean meal exhibits probiotic properties when included in Japanese quail diet in replacement of soybean meal | |
CN103734550B (en) | A kind of nursery pig concentrated feed | |
CN102870984A (en) | Feed for anthony pigs and preparation method thereof | |
CN104106740A (en) | Special feed for laying hens in young adulthood | |
CN103609899B (en) | Pig anti diar rhea growth promotion green feed additive and preparation method thereof | |
CN104489394B (en) | A kind of pig's feed additive improving immunologic function | |
CN104106739A (en) | High protein feed for laying ducks | |
CN105010872A (en) | Ostrich feed and production method thereof | |
CN109770078A (en) | A kind of feed addictive preventing nursing period calf diarrhea and its application method | |
CN111000035A (en) | Formula of compound feed and production process thereof | |
CN104522423B (en) | A kind of 45% small child care concentrate feed and preparation method thereof | |
CN102870985A (en) | Feed for breast-fed sows and preparation method thereof | |
CN104187147A (en) | Edible dog feed for improving digestion and enhancing immunity | |
CN107125441A (en) | A kind of feed addictive tannalbin, a kind of composite feed additive and a kind of feed | |
CN110892944A (en) | Weaned pig feed additive capable of replacing antibiotics and application thereof | |
CN104431619A (en) | Compound feed for preventing and treating three diseases of grass carp | |
JP2002360186A (en) | Growth promotant containing herb | |
CN112655816A (en) | Feed additive for preventing and treating bovine frog ascites disease and preparation method and application thereof | |
Dan et al. | Nutritional evaluation of soybean meal after fermentation with two fish gut bacterial strains, Bacillus cereus LRF5 and Staphylococcus caprae CCF2 in formulated diets for Labeo rohita fingerlings | |
CN110833120A (en) | Feed and preparation method thereof | |
CN115211492B (en) | Stress-resistant growth-promoting stress-relieving medicine for livestock and poultry, and preparation method and application thereof | |
CN105795136A (en) | Pig feed additive for earlier stage of fattening | |
CN102318762A (en) | Porket concentrated feed for two week feeding after ablactation and preparation method thereof | |
CN115462478A (en) | Abalone compound feed for enhancing immunity and improving intestinal flora and application thereof | |
CN104982674A (en) | Preparation method of probiotic fermentation duck feed additive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210416 |
|
RJ01 | Rejection of invention patent application after publication |